1.The Clinical Utility of MicroRNA as a Prognostic Biomarker of Pancreatobiliary Cancers.
Gut and Liver 2016;10(5):663-664
No abstract available.
MicroRNAs*
2.Translation: MicroRNA Signatures as Diagnostic and Therapeutic Targets.
Scott A WALDMAN ; Andre TERZIC
Laboratory Medicine Online 2011;1(1):1-2
No abstract available.
MicroRNAs
3.A New Member of Myocardial Ischemia-Reperfusion (MI/R) Associated miRNAs, miR-484: Its Potential Cardiac Protection Role
Korean Circulation Journal 2020;50(3):264-266
No abstract available.
MicroRNAs
4.The relevance of micrornas in vascular aging
Journal of University of Malaya Medical Centre 2014;17(2):1-6
MicroRNAs (miRNAs) are short, single-stranded non-coding RNAs that control gene expression by annealing
to complementary sequences in mRNAs. They are estimated to regulate at least one third of human
transcripts and hence, manipulation of these miRNAs can profoundly affect the proteome and ultimately
cellular phenotypes. A substantial amount of work has shed light on the crucial roles of miRNAs in diseases.
miRNA expression profiles between normal and diseased tissues have identified miRNA signature patterns
that correlate to disease development and progression. This review discusses some of the important miRNAs
that are involved in endothelial cell senescence and dysfunction that contribute to the development and
progression of cardiovascular diseases.
MicroRNAs
6.miR-155 EXPRESSION UTILIZATION AS A POTENTIAL DIAGNOSTIC BIOMARKER OF HEART FAILURE: A SYSTEMATIC REVIEW
Kevin Tandarto ; Ivander Tjendrawinata ; Norman Sukmadi ; Sidhi Laksono
Journal of University of Malaya Medical Centre 2023;26(1):105-114
Background:
Heart failure (HF) is a complex clinical syndrome with signs and symptoms resulting from any structural dysfunction of ventricular filling or blood ejection. miRNAs were known as essential regulators and tissue-specifically expressed. MicroRNA-155 (miR-155) expression in macrophages is already well known to promote hypertrophy, cardiac inflammation, and failure due to pressure overload. In this study, we aim to identify the role of expression miR-155 as a potential biomarker for HF.
Method:
We incorporated search engines from Google Scholar, PubMed, EBSCO Host, and ProQuest to search the articles. Newcastle Ottawa Scale (NOS) was used to evaluate the bias risk in the case-control research. A systematic database search reveals 6 relevant studies.
Results:
This research found that miR-155 levels were significantly higher in heart failure patients than in the MI and control groups. MiR-155's plasma levels in heart failure are higher than the control group, with a cut-off value of 0.8591, a sensitivity value of 98.5%, and a specificity value of 64.6%. However, miRNA expression patterns do not appear to differ significantly between pf and cf LVAD. Most cardiac changes and clinical outcomes specific to each device are independent of differences in miRNA expression levels. According to one study, miR-155, a diagnostic biomarker for heart failure, had a specificity of 92.14% and a cutoff value of 1.77%.
Conclusion
Our systematic review showed that miR-155 could be a potential new diagnostic biomarker in HF patients.
MicroRNAs
7.Dysregulated MicroRNA Expression in Irritable Bowel Syndrome.
Journal of Neurogastroenterology and Motility 2016;22(2):166-167
No abstract available.
Irritable Bowel Syndrome*
;
MicroRNAs*
Result Analysis
Print
Save
E-mail